ETP Fund
VC Fund
ETP Fund is a VC fund focused on Biotechnology and Medical. ETP Fund
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries ETP Fund invests in
Stages ETP Fund invests in
Countries ETP Fund invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Wellness 1 (25%)
- Health Care 1 (25%)
- Therapeutics 1 (25%)
Stage
- Series B 2 (50%)
- Series A 1 (25%)
- Post-IPO Equity 1 (25%)
Country
- United States 2 (50%)
- China 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Sophonix focuses on the development, production and sales of in vitro diagnostic instruments and reagents, providing accurate POCT solutions. | $14.2M / Series B / Jun 23, 2020 | |
|
|
Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $25M / Series B / Feb 01, 2019 | |
|
|
CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augmentits hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise. | $50M / Post-IPO Equity / Mar 20, 2018 | |
|
|
Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $6.1M / Series A / Feb 08, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does ETP Fund invest in?
ETP Fund invests primarily in Biotechnology, Medical and Wellness startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did ETP Fund last invest?
The most recent investment recorded for ETP Fund closed in Jun 2020. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!